Edgar Filing: INTEGRATED BIOPHARMA INC - Form 4

INTEGRAT Form 4 June 04, 201	TED BIOPHARM 15	A INC	J							
OMB APPR										
	STATES	S SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549					NOMB Number:	3235-0287		
Check the if no lon subject to Section Form 4	nger STATEN 16.	AENT OI	Expires: Estimated burden hou response	urs per						
may con	Form 5 obligations may continue.Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,See InstructionSection 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940									
(Thit of Type	(Kesponses)									
1. Name and Address of Reporting Person <u>*</u> Masi Dina			2. Issuer Name and Ticker or Trading Symbol INTEGRATED BIOPHARMA INC [INBP.OB]			5. Relationship of Reporting Person(s) to IssuerC (Check all applicable)				
(Least)	(Einst)	Middle)	-	-			Director	100	% Owner	
(Last) (First) (Middle) 14 LEXINGTON WAY						Diffect (give title Other (specify below) below) CFO				
	4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 						
LONG VA	LLEY, NJ 07853						Person		epotting	
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any	Date, if	3. Transactio Code (Instr. 8)	Disposed	(A) or of (D) 4 and 5) (A) or	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amount	(D) Price	()			
Reminder: Re	port on a separate line	e for each cl	ass of sec	urities bene	ficially ow	ned directly of	or indirectly.			
					inforr requi	nation cont red to resp	spond to the colle ained in this form ond unless the for ntly valid OMB co	i are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

number.

Edgar Filing: INTEGRATED BIOPHARMA INC - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8)	Acquired (A Disposed of (Instr. 3, 4, 5)	f (D)				
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amoun Numbe Shares
STOCK OPTION (RIGHT TO BUY)	\$ 0.09	06/02/2015		А	250,000		<u>(1)</u>	06/02/2025	COMMON STOCK	250,0

Reporting Owners

Reporting Owner Name / Address	Relationships					
1 8	Director	10% Owner	Officer	Other		
Masi Dina 14 LEXINGTON WAY LONG VALLEY, NJ 07853			CFO			

Signatures

/S/ DINA MASI 06/04/2015 **Signature of Date Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) (1) The option vests 75% (187,500) on grant date (June 2, 2015) and in three equal annual installments for the remaining 25% (62,500) beginning on June 2, 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.